Gland Pharma Limited FY25 Results: Margins Hold Strong, Strategy Gathers Steam Financial Highlights: - FY25 Revenue: 5,617 Cr (1% YoY) - EBITDA Margin: 1,269 Cr (5% YoY) | Margin 23% - PAT: 698 Cr (10% YoY) | Margin at 12% - Dividend: 18/share final dividend recommended Business Highlights: - 31 product launches in FY25, including new molecules like Latanoprost & Dexamethasone - 32 ANDA approvals, 24 filings U.S
Take the Next StepThe OASIS Advantage Are you tired of pain, fatigue, and insurance denials
As of time of publication, all further trials were happening in China with no phase 2 or 3 trials active anywhere else
Your doctor probably told you to stop taking it for a little while
Promotes tendon-to-bone healing and collagen organization in rat models at levels comparable to or exceeding the bodys natural regenerative processes after injury
Cold acclimation via the KQT-2 potassium channel is modulated by oxygen in Caenorhabditis elegans